Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

fludarabine phosphate 2fludarabine 2Lenalidomide 2Cyclophosphamide 2sargramostim 1plerixafor 1pegylated granulocyte colony-stimulating factor 1montanide ISA 51 1incomplete Freund's adjuvant 1ferric pyrophosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Whole-Body Irradiation 1Stem Cell Transplantation 1Specimen Handling 1Melphalan 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1High-Throughput Screening Assays 1Fluorodeoxyglucose F18 1Dexamethasone 1Cyclosporine 1Colony-Stimulating Factors 1Calcium Dobesilate 1Budesonide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × High-Throughput Screening Assays × 30 days × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡